A practical reference on Nucleotide: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Nicotinamide mononucleotide, abbreviated NMN, is a naturally occurring nucleotide found in the cells of many organisms, including bacteria, plants, and mammals. Its structure consists of a nicotinamide ring attached to a ribose-phosphate group. NMN functions as an intermediate in the NAD+ salvage pathway, a recycling route that regenerates nicotinamide adenine dinucleotide. The enzyme nicotinamide phosphoribosyltransferase produces NMN from nicotinamide and phosphoribosyl pyrophosphate. A second enzyme, NMN adenylyltransferase, then converts NMN into NAD+.
Dietary sources of NMN include small amounts in certain vegetables, fruits, and other foods, although exact values vary by sample and method. Endogenous NMN concentrations are tightly regulated and often low, making measurement in blood or tissues technically demanding. After oral intake, NMN is thought to be rapidly metabolized in the intestine and liver, and intact NMN may not reach all tissues at high levels. Some rodent studies report increases in tissue NAD+ after oral NMN, while human data remain limited and sometimes rely on blood NAD+ metabolites rather than direct tissue measures.
Research on NMN has focused on aging, metabolic regulation, exercise capacity, and insulin sensitivity, but findings are preliminary. Many human trials are small, short in duration, and use different endpoints, which complicates comparison across studies. No national regulator has approved NMN as a therapeutic drug for any indication. In some countries it is sold as a supplement or research chemical, while other jurisdictions have questioned its status under food or supplement laws. Claims about extending human lifespan or reversing aging are not supported by established clinical evidence.
Solid NMN is generally handled as a moisture-sensitive and light-sensitive material. Suppliers commonly recommend storage at minus 20 degrees Celsius in a sealed, desiccated container, protected from light. Aqueous solutions are less stable than the solid and may degrade faster at elevated temperatures or extreme pH values. Because NMN contains a phosphate ester and a glycosidic bond, hydrolysis and other degradation pathways are plausible under unfavorable conditions. Stability data from independent laboratories remain limited, so handling recommendations often reflect supplier practice rather than published consensus.
Analytical measurement of NMN typically uses high-performance liquid chromatography with ultraviolet detection, often at a wavelength near 260 nanometers. Liquid chromatography coupled with tandem mass spectrometry provides greater sensitivity and specificity, especially for biological samples. Nuclear magnetic resonance spectroscopy can confirm structure and detect certain impurities. Purity values reported by suppliers depend on the analytical method, calibration standards, and whether related compounds such as nicotinamide or NAD+ are included in the calculation. Independent verification is useful because supplement labels may not fully describe the tested material.
Regulatory treatment of NMN differs by country and has changed over time. In the United States, the Food and Drug Administration has stated that NMN is excluded from the definition of a dietary supplement because it was investigated as a drug before being marketed as a supplement; enforcement and legal interpretation continue to evolve. In the European Union, NMN may require authorization as a novel food before sale. In Japan, NMN has been marketed in some food products, while it is not approved as a therapeutic drug in major markets. These categories affect labeling, permitted claims, and quality oversight.
| Property | Value | Notes |
|---|---|---|
| Chemical name | Nicotinamide mononucleotide | Nucleotide intermediate in NAD+ salvage pathway |
| Common abbreviation | NMN | Also written as β-NMN |
| Molecular formula | C11H15N2O8P | Uncharged parent form |
| Molar mass | 334.22 g/mol | Calculated from formula |
| CAS Registry Number | 1094-61-7 | For β-nicotinamide mononucleotide |
Nicotinamide mononucleotide, commonly abbreviated NMN, is a naturally occurring nucleotide. Its structure combines a nicotinamide ring with a ribose sugar and a phosphate group. The compound appears in cells across many organisms as an intermediate in the production of nicotinamide adenine dinucleotide, or NAD+. Because NMN sits close to NAD+ in metabolism, it has drawn interest in biochemistry and aging research. The molecule is not a dietary essential nutrient in the classical sense, and its presence in food is generally low and variable.
NAD+ serves as a coenzyme in redox reactions and as a substrate for enzymes involved in DNA repair and cellular signaling. In the salvage pathway, nicotinamide is converted to NMN by the enzyme NAMPT. NMN is then converted to NAD+ by NMNAT enzymes. A separate route links nicotinamide riboside to NMN through phosphorylation. These pathways maintain NAD+ levels, which can decline with age or metabolic stress in some tissues. The relative contribution of circulating NMN to tissue NAD+ remains an active area of study.
Solid NMN is a polar, water-soluble nucleotide that can absorb moisture from air. Its phosphate ester is susceptible to hydrolysis, and degradation is faster in aqueous solution, under strongly acidic or alkaline conditions, and at elevated temperatures. For laboratory and commercial handling, the solid is typically kept desiccated, protected from light, and stored frozen. Repeated freeze-thaw cycles can introduce moisture and accelerate breakdown. Stability data for specific formulations should be generated rather than assumed from the parent compound.
Identity and purity of NMN are commonly assessed by liquid chromatography with ultraviolet detection or mass spectrometry. High-performance liquid chromatography can separate related impurities such as nicotinamide, nicotinamide riboside, and NAD+ depending on the method. Mass spectrometry provides molecular mass confirmation, while nuclear magnetic resonance spectroscopy helps establish structure and anomeric form. Quantitative assays often use calibration curves and, in biological samples, stable isotope-labeled internal standards. Method validation addresses specificity, linearity, accuracy, precision, and limits of detection.
Navid Kermani (German: [naˈviːd kɛʁˈmaːni]; Persian: نوید کرمانی; [næˈviːd keɾmɒːˈniː]; born 27 November 1967 in Siegen) is a German writer and orientalist. He is the author of several novels as well as books and essays on Islam, the Middle East and Christian-Muslim dialogue. He has won numerous prizes for his literary and academic work, including the Peace Prize of the German Publishers' Association on 18 June 2015.
== Detection of citrullinated peptides and proteins == Citrullinated peptides and proteins can be detected using antibodies targeting the citrullinated residues, or detected using mass spectrometry-based proteomics technologies. Citrullination of arginine results in a monoisotopic mass increase of +0.984016 Da, which can be measured with mass spectrometry. The mass shift is close to the mass difference between the different peptide isotopes of +1.008665 which can be mistaken for a citrullinated peptide, especially on low-resolution instruments. However, this is less of an issue with modern high resolution/high accuracy mass spectrometers. Furthermore, the mass shift is identical to the mass shift caused by deamidation of the amino acid asparagine or glutamine side chain, which are common modifications. Citrulline residues can be chemically modified with butanedione or by biotinylation prior to analysis, leading to a different mass shift, and this strategy has successfully been used to facilitate identification by mass spectrometry. Another approach is to utilize the neutral loss of isocyanic acid (HNCO) from citrulline residues when submitted to low energy collision induced dissociation fragmentation in mass spectrometers. The loss causes a mass shift of −43.0058 Da, which can be utilized by mass spectrometers to predominantly select citrullinated peptides for fragmentation (sequencing). Finally, the loss of positive charge at physiological pH caused by citrullination can be utilized. Prior to bottom-up proteomics analysis, proteins are enzymatically cleaved into peptides.
== Interactions == Unlike cimetidine, the first H2 antagonist, famotidine has a minimal effect on the cytochrome P450 enzyme system and does not appear to interact with as many drugs as other medications in its class. Some exceptions include antiretrovirals such as atazanavir, chemotherapeutics such as doxorubicin, and antifungal medications such as itraconazole.
Sources: en.wikipedia.org
In 2020, urea derivative 3 (Table 1) was identified via high-throughput screening (HTS), as a competitive inhibitor of ERAP1 aminopeptidase activity (IC50 = 6.9 μM) with increased selectivity over ERAP2 and IRAP. SAR exploration and docking studies showed that the N-acetylpiperazine carbonyl group was critical for the activity via its zinc-binding group properties.
Qualitatively the shape of the atomic orbitals of multi-electron atoms resemble the states of the hydrogen atom. The Pauli principle requires the distribution of these electrons within the atomic orbitals such that no more than two electrons are assigned to any one orbital; this requirement profoundly affects the atomic properties and ultimately the bonding of atoms into molecules.
In 1959 Ernst Freese coined the terms "transitions" or "transversions" to categorize different types of point mutations. Transitions are replacement of a purine base with another purine or replacement of a pyrimidine with another pyrimidine. Transversions are replacement of a purine with a pyrimidine or vice versa. There is a systematic difference in mutation rates for transitions (Alpha) and transversions (Beta). Transition mutations are about ten times more common than transversions.
Sources: en.wikipedia.org
Szára, who later worked for the United States National Institutes of Health, researched DMT after his order to acquire LSD from the Swiss company Sandoz Laboratories was rejected on the grounds that the powerful psychotropic could be dangerous in the hands of a communist country. In his paper Dimethyltryptamin: Its Metabolism in Man; the Relation of its Psychotic Effect to the Serotonin Metabolism, Szara employed synthetic DMT, synthesized by the Speeter–Anthony route, which was then administered to 20 volunteers by intramuscular injection. Urine samples were collected from these volunteers for the identification of DMT metabolites. This is considered to be the link between the chemical structure of DMT and its cultural consumption as a psychoactive and religious sacrament. Another historical milestone was the discovery of DMT in plants frequently used by Amazonian natives as additive to the vine Banisteriopsis caapi to make ayahuasca decoctions. In 1957, American chemists Francis Hochstein and Anita Paradies identified DMT in an "aqueous extract" of leaves of a plant they named Prestonia amazonicum [sic] and described as "commonly mixed" with B. caapi. The lack of a proper botanical identification of Prestonia amazonica in this study led American ethnobotanist Richard Evans Schultes (1915–2001) and other scientists to raise serious doubts about the claimed plant identity. The mistake likely led the writer William Burroughs to regard the DMT he experimented with in Tangier in 1961 as "Prestonia".
Roeder and Robert Tjian, for their outstanding work on eukaryotic transcription regulation 1993 James E. Rothman and Randy Schekman, for determining the components of the secretory pathway 1992 Paul Nurse and Leland H. Hartwell, for establishing the details of the control of eukaryotic cell cycle 1991 David Botstein, Raymond L. White and Ronald W. Davis, for creating the methods by which variations in the human genome can be detected and analyzed 1990 Richard Henderson and Peter Nigel Tripp Unwin, for determining the first structure of an integral membrane protein 1989 Christiane Nüsslein-Volhard and Edward B. Lewis, for pioneering studies of eukaryotic development 1988 Sidney Altman and Thomas R. Cech, for discovering RNA catalysis 1987 Shinya Inoué, for his innovations in light microscopy 1986 Harland G. Wood, for his outstanding work on enzyme function 1985 Seymour Benzer and Sydney Brenner, for founding modern eukaryotic genetics 1984 Donald D. Brown and Robert L. Letsinger, for their seminal work on development 1983 Eric R. Kandel and Daniel E. Koshland, Jr., for pioneering contributions to sensory transduction 1982 Keith R. Porter and Alexander Rich 1981 Stanley Cohen, Rita Levi-Montalcini and Gordon H. Sato 1980 Elias J. Corey, Bengt I. Samuelsson and Frank H. Westheimer 1979 Howard Green and Beatrice Mintz 1978 César Milstein 1977 Barbara McClintock 1976 Peter D. Mitchell 1975 Bruce Ames, James A. Miller and Elizabeth C. Miller 1974 Arthur B. Pardee and H. Edwin Umbarger 1973 H. Ronald Kaback and Saul Roseman 1972 Boris Ephrussi 1971 David H. Hubel and Torsten N.
== Early life and education == Melo was born on 24 July 1958. He was born and raised in Piracanjuba, in the interior of the state of Goiás. He moved to Porto Alegre in February 1978. He is married to Valéria Leopoldino, with whom he has two children: Pablo Melo and João Arthur. He graduated with a law degree from Unisinos.
Sources: en.wikipedia.org
NMN is nicotinamide mononucleotide, a nucleotide intermediate in the NAD+ salvage pathway. Cells use it to help regenerate NAD+, a coenzyme involved in energy metabolism and cellular signaling. It is present naturally in many organisms and is also produced synthetically for research and consumer products.
NMN is the immediate precursor to NAD+ in the salvage pathway. The enzyme NMN adenylyltransferase adds an adenylate group to NMN to form NAD+. Because NAD+ levels decline with age in some tissues, researchers study whether raising NMN availability can influence NAD+ metabolism.
No. Human evidence is limited, and no regulatory agency has approved NMN for treating or preventing aging. Some trials measure NAD+ metabolites or metabolic markers, but their results do not establish a clinical benefit. Larger, longer studies with standardized endpoints are needed.
Solid NMN is commonly stored frozen at about minus 20 degrees Celsius, sealed against moisture, and protected from light. Solutions are typically prepared fresh because they can degrade more quickly. Specific storage conditions can vary by supplier and intended use.